JP2019510746A5 - - Google Patents

Download PDF

Info

Publication number
JP2019510746A5
JP2019510746A5 JP2018544835A JP2018544835A JP2019510746A5 JP 2019510746 A5 JP2019510746 A5 JP 2019510746A5 JP 2018544835 A JP2018544835 A JP 2018544835A JP 2018544835 A JP2018544835 A JP 2018544835A JP 2019510746 A5 JP2019510746 A5 JP 2019510746A5
Authority
JP
Japan
Prior art keywords
idh1
flt3
inhibitor
composition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018544835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510746A (ja
JP6856657B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/064845 external-priority patent/WO2017146795A1/en
Publication of JP2019510746A publication Critical patent/JP2019510746A/ja
Publication of JP2019510746A5 publication Critical patent/JP2019510746A5/ja
Priority to JP2021044546A priority Critical patent/JP2021102630A/ja
Application granted granted Critical
Publication of JP6856657B2 publication Critical patent/JP6856657B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018544835A 2016-02-26 2016-12-02 血液学的悪性疾患および固形腫瘍の処置のためのｉｄｈ１阻害剤 Expired - Fee Related JP6856657B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021044546A JP2021102630A (ja) 2016-02-26 2021-03-18 血液学的悪性疾患および固形腫瘍の処置のためのｉｄｈ１阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662300673P 2016-02-26 2016-02-26
US62/300,673 2016-02-26
PCT/US2016/064845 WO2017146795A1 (en) 2016-02-26 2016-12-02 Idh1 inhibitors for the treatment of haematological malignancies and solid tumours

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021044546A Division JP2021102630A (ja) 2016-02-26 2021-03-18 血液学的悪性疾患および固形腫瘍の処置のためのｉｄｈ１阻害剤

Publications (3)

Publication Number Publication Date
JP2019510746A JP2019510746A (ja) 2019-04-18
JP2019510746A5 true JP2019510746A5 (cg-RX-API-DMAC10.html) 2020-01-16
JP6856657B2 JP6856657B2 (ja) 2021-04-07

Family

ID=57610404

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018544781A Expired - Fee Related JP6930991B2 (ja) 2016-02-26 2016-12-02 血液学的悪性腫瘍及び固形腫瘍の治療のためのｉｄｈ２阻害剤
JP2018544835A Expired - Fee Related JP6856657B2 (ja) 2016-02-26 2016-12-02 血液学的悪性疾患および固形腫瘍の処置のためのｉｄｈ１阻害剤
JP2021044546A Withdrawn JP2021102630A (ja) 2016-02-26 2021-03-18 血液学的悪性疾患および固形腫瘍の処置のためのｉｄｈ１阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018544781A Expired - Fee Related JP6930991B2 (ja) 2016-02-26 2016-12-02 血液学的悪性腫瘍及び固形腫瘍の治療のためのｉｄｈ２阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021044546A Withdrawn JP2021102630A (ja) 2016-02-26 2021-03-18 血液学的悪性疾患および固形腫瘍の処置のためのｉｄｈ１阻害剤

Country Status (12)

Country Link
US (3) US10137130B2 (cg-RX-API-DMAC10.html)
EP (2) EP3419593B1 (cg-RX-API-DMAC10.html)
JP (3) JP6930991B2 (cg-RX-API-DMAC10.html)
KR (2) KR20180113540A (cg-RX-API-DMAC10.html)
CN (1) CN109069410B (cg-RX-API-DMAC10.html)
AU (2) AU2016393869B2 (cg-RX-API-DMAC10.html)
CA (2) CA3015753A1 (cg-RX-API-DMAC10.html)
ES (1) ES2912909T3 (cg-RX-API-DMAC10.html)
IL (2) IL261353A (cg-RX-API-DMAC10.html)
MA (1) MA43640A (cg-RX-API-DMAC10.html)
MX (3) MX390396B (cg-RX-API-DMAC10.html)
WO (2) WO2017146794A1 (cg-RX-API-DMAC10.html)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
PH12021551647A1 (en) 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
WO2016044787A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
CA2961807A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HUE062424T2 (hu) 2014-09-19 2023-11-28 Forma Therapeutics Inc Piridin-2(1H)-on kinolinon származékok mint mutáns izocitrát dehidrogenáz inhibitorok
WO2016044781A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
AU2015324158A1 (en) 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9624175B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US10407419B2 (en) 2015-04-21 2019-09-10 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
MD3362066T2 (ro) 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
JP2018534288A (ja) 2015-10-15 2018-11-22 アジオス ファーマシューティカルズ， インコーポレイテッド 悪性腫瘍の治療のための併用療法
CA3002029A1 (en) 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
HUE067449T2 (hu) 2015-10-15 2024-10-28 Servier Lab Ivozidenib, citarabin és daunorubicin vagy idarubicin kombinációs terápa akut mielogén leukémia kezelésére
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
WO2018026894A1 (en) * 2016-08-03 2018-02-08 Celgene Corporation Methods of treatment of myelodysplastic syndrome
KR102498693B1 (ko) 2016-09-07 2023-02-10 셀진 코포레이션 정제 조성물
WO2018204787A1 (en) * 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
US11709164B2 (en) 2017-10-26 2023-07-25 National University Of Singapore Approach for universal monitoring of minimal residual disease in acute myeloid leukemia
WO2019109095A1 (en) * 2017-12-01 2019-06-06 Beth Israel Deaconess Medical Center, Inc. Arsenic trioxide and retinoic acid compounds for treatment of idh2-associated disorders
EP3746124A4 (en) 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
SMT202300073T1 (it) 2018-05-16 2023-05-12 Forma Therapeutics Inc Inibizione di idh-1 mutante
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CA3103498A1 (en) * 2018-07-06 2020-01-09 Agios Pharmaceuticals, Inc. Ivosidenib forms and pharmaceutical compositions
US20210299233A1 (en) * 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
EP3875090A4 (en) * 2018-10-31 2021-12-22 FUJIFILM Corporation PELLET CONTAINING AN ANTITUMOR AGENT
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020117867A1 (en) * 2018-12-03 2020-06-11 Beth Israel-Deaconess Medical Center, Inc. Darinaparsin and retinoic acid compounds for treatment of idh-associated disorders
WO2020117868A1 (en) * 2018-12-03 2020-06-11 Beth Israel-Deaconess Medical Center, Inc. Arsenic compounds and retinoic acid compounds for treatment of idh-associated disorders
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
IL330104A (en) 2019-03-11 2026-08-01 Deciphera Pharmaceuticals Llc Crystalline forms of rifatinib
KR102035481B1 (ko) 2019-04-12 2019-10-23 한국지질자원연구원 점토광물 복합체를 포함하는 염증성 대장염의 예방, 개선 및 치료용 조성물
US12691108B2 (en) 2019-08-12 2026-07-28 Deciphera Pharmaceuticals, Llc Methods for treating vascular malformations
HRP20260411T1 (hr) 2019-08-12 2026-05-08 Deciphera Pharmaceuticals, Llc Ripretinib za liječenje gastrointestinalnih stromalnih tumora
EP4041922A4 (en) 2019-10-07 2023-11-01 University Hospitals Cleveland Medical Center METHOD FOR TREATING WILD-TYPE ISOCITRATE DEHYDROGENASE-1 CANCER
CN112773797A (zh) * 2019-11-11 2021-05-11 江苏恒瑞医药股份有限公司 一种吡咯并六元杂环化合物在制备治疗flt3突变的肿瘤的药物中的用途
US20220401450A1 (en) * 2019-11-14 2022-12-22 Celgene Corporation Pediatric formulations for treatment of cancer
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
WO2021155264A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155262A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
AU2021242260B2 (en) * 2020-03-23 2023-12-14 Eli Lilly And Company Combination therapy with a mutant IDH inhibitor
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
EP4210766A4 (en) * 2020-09-14 2024-11-06 Totus Medicines Inc. THERAPEUTIC CONJUGATES
CN114681451B (zh) * 2020-11-10 2023-11-03 华熙生物科技股份有限公司 透明质酸或其盐和/或海藻糖的组合物及其在稳定麦角硫因中的用途
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2024249769A2 (en) * 2023-06-02 2024-12-05 Foghorn Therapeutics Inc. Combination therapy for treating hematological cancers
CN117838863B (zh) * 2023-12-26 2025-03-11 厦门大学 一种抑制d2hgdh的核酸分子、抑制剂及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CN102985557B (zh) 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
CN102438588B (zh) * 2009-03-23 2015-04-01 埃姆比特生物科学公司 使用联合治疗法治疗疾病的方法
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
SMT201800334T1 (it) 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
BR112015016282A2 (en) * 2013-01-07 2017-07-11 Arog Pharmaceuticals, Inc. crenolanib for treatment of mutated flt3 proliferative disorders
MX375030B (es) 2013-07-11 2025-03-06 Agios Pharmaceuticals Inc Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer.
CN105916507A (zh) 2013-08-02 2016-08-31 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
CA2842635A1 (en) 2014-01-20 2015-07-20 University Health Network Pre-cancerous cells and their identification in the prevention and treatment of cancer
WO2015127172A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015127173A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
PH12021551647A1 (en) * 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
SMT202100444T1 (it) 2014-03-14 2021-09-14 Les Laboratories Servier Sas Composizioni farmaceutiche di composti terapeuticamente attivi
AU2015324158A1 (en) 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN108349933A (zh) 2015-08-05 2018-07-31 安吉奥斯医药品有限公司 制备6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二醇和6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二胺的方法

Similar Documents

Publication Publication Date Title
JP2019513694A5 (cg-RX-API-DMAC10.html)
CN113874350B (zh) 作为缺氧可诱导因子-2(α)抑制剂的四氢-1H-环戊二烯并[CD]茚衍生物
JP2018535951A5 (cg-RX-API-DMAC10.html)
JP2019502669A5 (cg-RX-API-DMAC10.html)
EP4161511B1 (en) Novel small molecules for targeted degradation of untargetable kras in cancer therapy
JP2019507721A5 (cg-RX-API-DMAC10.html)
JP2021098740A5 (cg-RX-API-DMAC10.html)
CN115485262B (zh) 低氧诱导因子-2(α)抑制剂及其在疾病治疗中的用途
JP2018536636A5 (cg-RX-API-DMAC10.html)
JP2018534288A5 (cg-RX-API-DMAC10.html)
JP2019533670A5 (cg-RX-API-DMAC10.html)
JP2015508103A5 (cg-RX-API-DMAC10.html)
JP2017508805A5 (cg-RX-API-DMAC10.html)
JP2022532850A5 (cg-RX-API-DMAC10.html)
IL293934A (en) Biomarkers for cancer therapy using mdm2 antagonists
CN111918652A (zh) 用于治疗eb病毒阳性的癌症的趋化因子受体调节剂
CN110582581A (zh) 用于治疗过度增殖性疾病的方法中的atr激酶的抑制剂
US20240293364A1 (en) Biomarkers for cancer therapy using mdm2 antagonists
TW202317074A (zh) 製備３－氟－５－（（（１Ｓ，２ａＲ）－１，３，３，４，４－五氟－２ａ－羥基－２，２ａ，３，４－四氫－１Ｈ－環戊二烯并［ＣＤ］茚－７－基）氧基）苄腈及其多晶型物之方法
JP2008519049A5 (cg-RX-API-DMAC10.html)
US20220185771A1 (en) Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases
JP2024520461A (ja) Ｅｇｆｒ及び／又はｈｅｒ２に異常を有するがんを有する対象の治療方法
JP2023063189A5 (cg-RX-API-DMAC10.html)
US20240336563A1 (en) G-alpha-s inhibitors and uses thereof
JP2021521132A5 (cg-RX-API-DMAC10.html)